The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mintern, J. D.
Right arrow Articles by Heath, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mintern, J. D.
Right arrow Articles by Heath, W. R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stem Cells
The Journal of Immunology, 2002, 168: 977-980.
Copyright © 2002 by The American Association of Immunologists

Cutting Edge

Cutting Edge: Precursor Frequency Affects the Helper Dependence of Cytotoxic T Cells1

Justine D. Mintern*,{ddagger}, Gayle M. Davey*, Gabrielle T. Belz*, Francis R. Carbone{dagger} and William R. Heath2,*,{ddagger}

* Immunology Division, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, and {dagger} Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia; and {ddagger} Cooperative Research Center for Vaccine Technology, Queensland Institute of Medical Research, Royal Brisbane Hospital, Herston, Queensland, Australia


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
Generation of CTL immunity often depends on the availability of CD4 T cell help. In this report, we show that CTL responses induced by cross-priming can be converted from CD4-dependent to CD4-independent by increasing the frequency of CTL precursors. In the absence of CD4 T cells, high numbers of CTL precursors were able to expand in number and become effector CTL. The ability of high frequencies of CD8 T cells to override help was not due to their ability to signal CD40 via expression of CD154. These findings suggest that when precursor frequencies are high, priming of CD8 T cell responses may not require CD4 T cell help.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Generation of CTL immunity, particularly by cross-priming, often requires help from CD4 T cells (1, 2, 3, 4, 5, 6). However, many viruses can generate CTL immunity in the absence of such helper cells (7, 8, 9). Early in vitro studies examining the cooperation between CD4 and CD8 T cells revealed a role for IL-2 as a helper factor (1). This idea was strengthened by in vivo studies showing that the provision of IL-2 could support the survival of CD8 T cells (10) or stimulate their capacity to induce autoimmunity (11). However, none of these studies provided direct evidence that IL-2 was the helper factor provided by CD4 T cells in vivo. Some doubt as to the soluble nature of help was raised by evidence that CD4 and CD8 T cells needed to recognize Ag presented by the same APC (1, 3). Although this did not exclude a role for a soluble signal, it favored the view that help is mediated via a CD4 T cell-dependent modification, or "licensing," of the APC, as originally proposed by Guerder and Matzinger (12). Direct evidence for this licensing model was provided by three different groups including ourselves, who showed that CD4 help was mediated by signaling CD40 on the APC (5, 13, 14). In this model, the CD4 T cells recognize their class II-restricted ligand, up-regulate CD154, and then signal CD40 on the APC. Once signaled via CD40, the APC is fully licensed to prime a naive CD8 T cell.

Since identification of the CD154/CD40-helper pathway for CTL induction, other alternative pathways have been reported. Several groups have provided evidence that RANK (TRANCE receptor, OPG) and RANKL can function in a similar way to CD154/CD40 for licensing dendritic cells (15). Furthermore, Pardoll and colleagues (16) provided in vitro evidence for a soluble helper factor that was not IL-2. To what degree each of these and other unidentified molecular interactions contribute to CD4 T cell-mediated help for CTL induction is unclear, but probably depends on the circumstances in which priming takes place.

To better understand the requirements for help during CTL induction, we began examining the fate of CTL when cross-primed by OVA-coated spleen cells (17) in the absence of help. To do this, we used the OVA-specific CD8 T cells from OT-I transgenic mice (18, 19) to follow naive precursors primed in the absence of help. To our surprise, these precursors were able to respond normally to priming in the absence of CD4 T cells, leading us to discover that the CTL precursor frequency dramatically affected the dependence on CD4 T cell help.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Mice

All mice used were between 6 and 12 wk old, and were bred and maintained at the Walter and Eliza Hall Institute for Medical Research (Parkville, Victoria, Australia). Rag-1-deficient OT-I mice (20) and class II-deficient mice (21) have been described. Rag-1-deficient OT-I mice have been back-crossed to C57BL/6 eight generations. CD154-deficient OT-I mice were generated by intercrossing OT-I and CD154-deficient mice. These mice were three to nine generations back-crossed to C57BL/6. Ly5.1 congenic OT-I mice were generated by intercrossing OT-I and Ly5.1 congenic C57BL/6 mice.

Priming of mice

For priming mice with cell-associated OVA (17), bm1 spleen cells (2 x 108/ml) were incubated with 10 mg/ml OVA for 10 min at 37°C. Cells were washed, irradiated for 1000 rad, and after two more washes, 20 x 106 cells were injected i.v. into mice. The cells used to prime were referred to as OVA-coated spleen cells.

Preparation of OT-Is for adoptive transfer

OT-I cells were prepared as described (22, 23). Briefly, OT-I cells were derived from the spleen and lymph nodes of Rag-1-deficient OT-I mice. Cells were treated with RL172 (anti-CD4) and J11d (anti-heat stable Ag) for 30 min on ice, centrifuged, and then depleted by treatment with rabbit complement for 20 min at 37°C. Prepared cells were examined by flow cytometry for the proportion of V{alpha}2+CD8+ cells to determine the number of OT-I cells for adoptive transfer.

Fluorescent labeling of OT-I cells

CFSE-labeling was performed as previously described (24). Briefly, semipurified OT-I cells were resuspended in PBS containing 0.1% BSA (Sigma Aldrich, St. Louis, MO) at 107 cells/ml. For fluorescence-labeling, 1 µl of a CFSE (Molecular Probes, Eugene, OR) stock solution (5 mM in DMSO) was incubated with 107 cells for 10 min at 37°C.

Assessment of OT-I numbers

Cells from pooled lymph node and spleen were stained using the following mAbs: PE-conjugated anti-CD8 (YTS 169.4; Caltag Labortatories, San Francisco, CA), FITC-conjugated anti-V{beta}5.1/2 TCR (MR9-4; Ref. 24), and biotinylated anti-V{alpha}2 TCR (B20.1; Ref. 25). mAbs were conjugated to biotin or FITC using standard protocols. Biotin-labeled mAbs were detected with streptavidin-Tricolor (Caltag Laboratories). Analysis was performed on a FACScan (BD Biosciences, Mountain View, CA). Live gates were set on lymphocytes by forward and side scatter profiles. A total of 10,000–20,000 live cells were collected for analysis. OT-I T cells were identified as CD8+, V{alpha}2+, and V{beta}5+. This proportion in a noninjected recipient was <2%. CD8+, V{alpha}2+, and V{beta}5+ T cells above this background were considered to be OT-I T cells.

OVA-specific CTL generation

OVA-specific CTL were generated as previously described (3). Briefly, B6 mice were primed with OVA-coated spleen cells. After 7 days, spleens were removed and single cells were cultured with 108 1500 rad-irradiated OVA257–264-coated B6 spleen cells for 6 days. Cytotoxicity was assessed in a conventional 51Cr-release assay using the H-2b cell line EL4 with and without OVA-peptide-coating as targets. The percentage of OVA-specific lysis represents the lysis of peptide-coated EL4 minus the lysis of EL4 alone, i.e., peptide-dependent lysis. Lysis of unlabeled EL4 targets was <10% in all experiments. Lytic units were calculated by determining the minimum number of effectors required to generate 20% OVA-specific lysis and then dividing this into the total number of effectors generated per responder spleen.

Intracellular IFN-{gamma} staining

Staining for intracellular IFN-{gamma} was performed as previously described (26).


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
OT-I T cells proliferate in response to Ag in the absence of CD4 T cell help

As previously reported (17), B6 mice can generate OVA-specific CTL when primed with irradiated spleen cells either osmotically loaded or coated with whole OVA. This response is mediated by cross-priming, where host APC capture donor cells and cross-present associated OVA on both class I and class II molecules. Generation of CTL by this type of priming is CD4 dependent, and therefore cannot be achieved in class II-deficient mice (Fig. 1Go; Ref. 13). This observation prompted us to examine the fate of precursor CTL primed in the absence of help.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 1. Class II-deficient mice cannot be cross-primed with OVA-coated spleen cells. B6 mice (•) or class II-deficient mice ({circ}) were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells. CTL activity was determined as described in Materials and Methods. The percentage of OVA-specific lysis represents the lysis of peptide-coated EL4 minus the lysis of EL4 alone, i.e., peptide-dependent lysis. The data shown are representative of four experiments with one mouse per experimental group.

 
First, we examined whether in the absence of CD4 T cells, CTL precursors would recognize Ag and become sufficiently activated to undergo division. To do this, we transferred 2 x 106 CFSE-labeled OT-I T cells into class II-deficient recipients (CD4 T cell deficient), and assessed their ability to proliferate in response to priming with OVA-coated spleen cells. Fig. 2Go demonstrates that the OT-I T cells were capable of Ag-specific division, in the absence of a helper T cell population.



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 2. OT-I cells divide in response to Ag in the absence of CD4 T cells. C57BL/6 mice or class II-deficient mice were injected i.v. with 2 x 106 CFSE-labeled OT-I cells. The following day mice were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells. Three days later, these mice were killed, and their spleen cells were analyzed by flow cytometry. Profiles are gated on CD8+, CFSE+, and propidium iodide-negative cells. The data shown are representative of five experiments with two mice per experimental group.

 
Class II-deficient mice injected with transgenic OVA specific CD8 T cells (OT-I cells) can generate CTL after cross-priming

The ability of OT-I T cells to proliferate in response to Ag, independently of CD4 help, prompted us to examine whether this was accompanied by an expansion in number. To do this, 2 x 106 OT-I cells were transferred into class II-deficient recipients and the fate of the cells determined following cross-priming. The experiments shown measured the number of OT-I cells present at 2 wk after priming. However, similar results were also observed at 1 or 6 wk. Fig. 3Go, A and B, indicates that both normal and class II-deficient hosts showed an equivalent increase in the number of OT-I cells after cross-priming. The expansion of OT-I cells in class II-deficient mice was surprising, and had two alternative explanations: either 1) expansion was not accompanied by differentiation into effector CTL and the mice were still functionally unprimed, or 2) expansion was indicative of priming, and the behavior of these OT-I cells was different from that of a normal repertoire.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 3. OT-I cells can be primed in the absence of CD4 T cells. C57BL/6 mice (A) or class II-deficient mice (B) were injected i.v. with 2 x 106 OT-I cells. The following day mice were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells. The number of CD8+V{alpha}2+V{beta}5+ cells in the spleen and peripheral lymph nodes was determined by flow cytometry 14 days after priming. The data presented were obtained from three separate experiments with two to three mice per group. C, Class II-deficient mice were injected i.v. with 2 x 106 OT-I cells (•). The following day, these mice were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells, or left untreated ({circ}). CTL activity was determined as described in Materials and Methods. The percentage of OVA-specific lysis represents the lysis of peptide-coated target cells minus the lysis of target cells alone, i.e., peptide-dependent lysis. The data shown are representative of four separate experiments with two to three mice per experimental group.

 
To distinguish between these two possibilities, we examined the differentiation status of OT-I cells in primed class II-deficient mice. Class II-deficient mice were adoptively transferred with 2 x 106 OT-I cells and then either left unprimed or primed with OVA-coated spleen cells. Seven days later, spleen cells from these mice were restimulated for 6 days in vitro and their ability to lyse 51Cr-labeled target cells was assessed (Fig. 3GoC). Comparison of the response from primed vs unprimed mice revealed that OT-I cells transferred into class II-deficient mice were primed. Thus, along with expanding in number, the OT-I cells differentiated normally after priming, despite the absence of CD4 T cell help.

Large numbers of OT-I cells are required to allow priming in the absence of help

The above data indicated that adoptively transferred OT-I cells could be cross-primed in the absence of CD4 T cell help. There were two main explanations for why these transgenic cells were no longer helper dependent: either 1) OT-I cells were helper independent because they represented a very high affinity CTL, or 2) the presence of a large number of CTL precursors converted a helper-dependent response into a helper-independent response. To address this issue, class II-deficient mice were injected with 10-fold decreasing numbers of OT-I cells, from 106 to 104 cells, and then primed and assessed for CTL activity (Fig. 4Go). As shown, class II-deficient mice only generated CTL immunity when reconstituted with 106 OT-I cells. Because 105 OT-I cells are detectable by flow cytometry using tetramer-staining, but we cannot detect OVA-specific cells in a normal naive repertoire (data not shown), this number of OT-I cells must vastly out-number the normal frequency of precursors. Failure to detect priming at this frequency indicates OT-I cells do not have a special property that allows them to be primed in the absence of help, but rather it is the high precursor frequency achieved when 106 cells are transferred that enabled helper-independent priming.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 4. The frequency of OT-I cells affects their helper dependence. Class II-deficient mice were injected with 106 ({circ}), 105 ({triangleup}), or 104 ({square}) OT-I cells. The following day, the mice were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells. A C57BL/6 control which did not receive OT-I cells was also immunized (•). CTL activity was determined as described in Materials and Methods. The percentage of OVA-specific lysis represents the lysis of OVA peptide-coated target cells minus the lysis of target cells alone, i.e., peptide-dependent lysis. The data shown are representative of three separate experiments with one to two mice per experimental group.

 
CD154 is not required for large numbers of OT-I cells to overcome the requirement for help

As we and others have reported, CD4 T cells provide help for CTL via the expression of CD154, which signals CD40 on the cross-priming APC, converting it into a cell capable of CTL priming (5, 13, 14). We wondered whether large numbers of OT-I cells might provide their own help via expression of CD154, particularly since CD154 has been shown to be expressed by a minor population of CD8 T cells (27, 28, 29). This has been demonstrated to contribute to CD8 T cell expansion in mucosal tissues (30). To test this possibility, OT-I mice were backcrossed to CD154-deficient mice, and their ability to generate CTL immunity was examined. Like wild-type OT-I cells, high numbers of CD154 knockout OT-I cells were able to generate helper-independent CTL responses (Fig. 5Go). Therefore, the ability of OT-I cells to overcome the requirement for help at high doses is not mediated via CD154.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 5. The ability of high numbers of OT-I cells to be primed in the absence of CD4 T cell help is not dependent on CD154 expression. Class II-deficient mice were injected i.v. with 2 x 106 OT-I or CD154-deficient OT-I cells. The following day, mice were immunized i.v. with 20 x 106 irradiated OVA-coated bm1 spleen cells. CTL activity was determined as described in Materials and Methods. Each point represents an individual mouse and the bar represents the mean within that group. Fifteen lytic units was the minimum detectable response. Nonresponders are represented by points below the line drawn at 15 lytic units. The data shown are representative of four separate experiments with one to two mice per experimental group.

 
Concluding remarks

The data presented above support a model where the helper dependence of CTL responses can be strongly influenced by the frequency of naive CTL precursors. When frequencies are low, help is critical, but as the number of precursors increase, CTL immunity becomes helper independent. The ability of CD8 T cells to provide their own help at high precursor frequencies is consistent with a report that CD8 T cells can cause DC maturation (31), and the observation that CD8 T cells can boost the response of other CD8 T cells under some circumstances (32). In this study, we do not observe an essential role for a CD154 signal in the mechanism by which CD8 T cells help themselves. Perhaps the simplest explanation is that while single CD8 T cells are unable to make sufficient cytokines to facilitate their own expansion, multiple clones together might achieve local threshold concentrations. Whatever the reason for helper independence at high frequencies, our report provides a potential explanation for some of the variability in the helper dependence of CTL priming with different immunogens. If an immunogen is complicated, and therefore contains multiple CTL epitopes, then the frequency of CTL precursors may be high, and the response helper independent. This could, for example, apply to some anti-viral responses that appear to be helper independent (7, 8, 9). In contrast, if the immunogen is simple and contains few CTL epitopes, such as the case for OVA, then responses will most likely require CD4 T cell help (Fig. 1Go and Ref. 13).

The data presented in this report highlight the dramatic effect of frequency on the helper dependence of CTL. This report also highlights the issue that examination of naive CTL using high frequencies of TCR transgenic T cells must consider the potential contribution of increased frequency.


   Acknowledgments
 
We thank Tatiana Banjanin, Freda Karamalis, Loretta Clovedale, and Annette Alafacci for their technical assistance.


   Footnotes
 
1 This work was funded by National Institutes of Health Grant AI43347-01, the National Health and Medical Research Council of Australia, the Cooperative Research Centre for Vaccine Technology, and a Howard Hughes Medical Institute International Fellowship. Back

2 Address correspondence and reprint requests to Dr. William R. Heath, Immunology Division, The Walter and Eliza Hall Institute, P. O. Royal Melbourne Hospital, Parkville 3050, Victoria, Australia. E-mail address: heath{at}wehi.edu.au Back

Received for publication August 21, 2001. Accepted for publication November 26, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Keene, J. A., J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768.[Abstract/Free Full Text]
  2. von Herrath, M. G., M. Yokoyama, J. Dockter, M. B. Oldstone, J. L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072.[Abstract]
  3. Bennett, S. R., F. R. Carbone, F. Karamalis, J. F. Miller, W. R. Heath. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186:65.[Abstract/Free Full Text]
  4. Husmann, L. A., M. J. Bevan. 1988. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Ann. NY. Acad. Sci. 532:158.[Medline]
  5. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.[Medline]
  6. Cardin, R. D., J. W. Brooks, S. R. Sarawar, P. C. Doherty. 1996. Progressive loss of CD8+ T cell-mediated control of a {gamma}-herpesvirus in the absence of CD4+ T cells. J. Exp. Med. 184:863.[Abstract/Free Full Text]
  7. Buller, R. M., K. L. Holmes, A. Hugin, T. N. Frederickson, H. C. D. Morse. 1987. Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328:77.[Medline]
  8. Rahemtulla, A., W. P. Fung-Leung, M. W. Schilham, T. M. Kundig, S. R. Sambhara, A. Narendran, A. Arabian, A. Wakeham, C. J. Paige, R. M. Zinkernagel, et al 1991. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353:180.[Medline]
  9. Liu, Y., A. Mullbacher. 1989. The generation and activation of memory class I MHC restricted cytotoxic T cell responses to influenza A virus in vivo do not require CD4+ T cells. Immunol. Cell Biol. 67:413.
  10. Kirberg, J., L. Bruno, H. von Boehmer. 1993. CD4+8- help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur. J. Immunol. 23:1963.[Medline]
  11. Heath, W. R., J. Allison, M. W. Hoffmann, G. Schonrich, G. Hammerling, B. Arnold, J. F. Miller. 1992. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 359:547.[Medline]
  12. Guerder, S., P. Matzinger. 1992. A fail-safe mechanism for maintaining self-tolerance. J. Exp. Med. 176:553.[Abstract/Free Full Text]
  13. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.[Medline]
  14. Ridge, J. P., F. Di Rosa, P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474.[Medline]
  15. Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025.[Abstract/Free Full Text]
  16. Lu, Z., L. Yuan, X. Zhou, E. Sotomayor, H. I. Levitsky, D. M. Pardoll. 2000. CD40-independent pathways of T cell help for priming of CD8+ cytotoxic T lymphocytes. J. Exp. Med. 191:541.[Abstract/Free Full Text]
  17. Carbone, F. R., M. J. Bevan. 1990. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171:377.[Abstract/Free Full Text]
  18. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.[Medline]
  19. Clarke, S. M. R., M. Barnden, C. Kurts, F. R. Carbone, J. F. A. P. Miller, W. R. Heath. 2000. Characterisation of the OVA-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 78:110.[Medline]
  20. Hogquist, K. A., M. A. Gavin, M. J. Bevan. 1993. Positive selection of CD8+ T cells induced by major histocompatibility complex binding peptides in fetal thymic organ culture. J. Exp. Med. 177:1469.[Abstract/Free Full Text]
  21. Gosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, C. Benoist, D. Mathis. 1991. Mice lacking MHC class II molecules. Cell 66:1051.[Medline]
  22. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.[Abstract/Free Full Text]
  23. Kurts, C., H. Kosaka, F. R. Carbone, J. F. Miller, W. R. Heath. 1997. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J. Exp. Med. 186:239.[Abstract/Free Full Text]
  24. Bill, J., O. Kanagawa, J. Linten, Y. Utsunomiya, E. Palmer. 1990. Class I and class II MHC gene products differentially affect the fate of V{beta}5 bearing thymocytes. J. Mol. Cell. Immunol. 4:269.[Medline]
  25. Pircher, H., N. Rebai, M. Groettrup, C. Gregoire, D. E. Speiser, M. P. Happ, E. Palmer, R. M. Zinkernagel, H. Hengartner, B. Malissen. 1992. Preferential positive selection of V{alpha}2+ CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V{alpha}a haplotypes: determination with a V{alpha}2-specific monoclonal antibody. Eur. J. Immunol. 22:399.[Medline]
  26. Flynn, K. J., G. T. Belz, J. D. Altman, R. Ahmed, D. L. Woodland, P. C. Doherty. 1998. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8:683.[Medline]
  27. Hermann, P., C. Van-Kooten, C. Gaillard, J. Banchereau, D. Blanchard. 1995. CD40 ligand-positive CD8+ T cell clones allow B cell growth and differentiation. Eur. J. Immunol. 25:2972.[Medline]
  28. Cronin, D. C., R. Stack, F. W. Fitch. 1995. IL-4-producing CD8+ T cell clones can provide B cell help. J. Immunol. 154:3118.[Abstract]
  29. Sad, S., L. Krishnan, R. C. Bleackley, D. Kagi, H. Hengartner, T. R. Mosmann. 1997. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Eur. J. Immunol. 27:914.[Medline]
  30. Lefrancois, L., S. Olson, D. Masopust. 1999. A critical role for CD40-CD40 ligand interactions in amplification of the mucosal CD8 T cell response. J. Exp. Med. 190:1275.[Abstract/Free Full Text]
  31. Ruedl, C., M. Kopf, M. F. Bachmann. 1999. CD8+ T cells mediate CD40-independent maturation of dendritic cells in vivo. J. Exp. Med. 189:1875.[Abstract/Free Full Text]
  32. Sherritt, M. A., J. Gardner, S. L. Elliot, C. Schmidt, W. R. Heath, A. Suhbier. 2000. Effect of preexisting cytotoxic T lymphocytes on therapeutic vaccines. Eur. J. Immunol. 30:671.[Medline]



This article has been cited by other articles:


Home page
 BloodHome page
I. A. Parish, S. Rao, G. K. Smyth, T. Juelich, G. S. Denyer, G. M. Davey, A. Strasser, and W. R. Heath
The molecular signature of CD8+ T cells undergoing deletional tolerance
Blood, May 7, 2009; 113(19): 4575 - 4585.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Ryu, K. M. Jung, H. S. Yoo, T. W. Kim, S. Kim, J. Chang, and E. Y. Choi
Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60
Blood, April 30, 2009; 113(18): 4273 - 4280.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Schuler, E. Contassot, M. Irla, S. Hugues, O. Preynat-Seauve, F. Beermann, A. Donda, L.E. French, and B. Huard
Direct Presentation of a Melanocyte-Associated Antigen in Peripheral Lymph Nodes Induces Cytotoxic CD8+ T Cells
Cancer Res., October 15, 2008; 68(20): 8410 - 8418.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Jusforgues-Saklani, M. Uhl, N. Blachere, F. Lemaitre, O. Lantz, P. Bousso, D. Braun, J. J. Moon, and M. L. Albert
Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming
J. Immunol., September 1, 2008; 181(5): 3067 - 3076.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Y. Gerner, K. A. Casey, and M. F. Mescher
Defective MHC Class II Presentation by Dendritic Cells Limits CD4 T Cell Help for Antitumor CD8 T Cell Responses
J. Immunol., July 1, 2008; 181(1): 155 - 164.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. B. Watchmaker, J. A. Urban, E. Berk, Y. Nakamura, R. B. Mailliard, S. C. Watkins, S. M. van Ham, and P. Kalinski
Memory CD8+ T Cells Protect Dendritic Cells from CTL Killing
J. Immunol., March 15, 2008; 180(6): 3857 - 3865.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. E. Matthews, J. S. Qin, J. Yang, I. F. Hermans, M. J. Palmowski, V. Cerundolo, and F. Ronchese
Increasing the Survival of Dendritic Cells In Vivo Does Not Replace the Requirement for CD4+ T Cell Help during Primary CD8+ T Cell Responses
J. Immunol., November 1, 2007; 179(9): 5738 - 5747.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Zhai, Y. Wang, Z. Wu, and J. W. Kupiec-Weglinski
Defective Alloreactive CD8 T Cell Function and Memory Response in Allograft Recipients in the Absence of CD4 Help
J. Immunol., October 1, 2007; 179(7): 4529 - 4534.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Azadniv, K. Dugger, W. J. Bowers, C. Weaver, and I. N. Crispe
Imaging CD8+ T cell dynamics in vivo using a transgenic luciferase reporter
Int. Immunol., October 1, 2007; 19(10): 1165 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. May, T. Dao, J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, R. H. Zhang, P. Maslak, and D. A. Scheinberg
Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells
Clin. Cancer Res., August 1, 2007; 13(15): 4547 - 4555.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. H. Horne, M. A. Koester, K. Jayashankar, K. E. Lunsford, H. L. Dziema, and G. L. Bumgardner
Disparate Primary and Secondary Allospecific CD8+ T Cell Cytolytic Effector Function in the Presence or Absence of Host CD4+ T Cells
J. Immunol., July 1, 2007; 179(1): 80 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. G. H. Hernandez, L. Shen, and K. L. Rock
CD40-CD40 Ligand Interaction between Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses in the Absence of CD4+ T Cell Help
J. Immunol., March 1, 2007; 178(5): 2844 - 2852.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. L. Ford, B. H. Koehn, M. E. Wagener, W. Jiang, S. Gangappa, T. C. Pearson, and C. P. Larsen
Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation
J. Exp. Med., February 19, 2007; 204(2): 299 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng
Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer
Cancer Res., February 1, 2007; 67(3): 1291 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Seavey and T. R. Mosmann
Paternal Antigen-Bearing Cells Transferred during Insemination Do Not Stimulate Anti-Paternal CD8+ T Cells: Role of Estradiol in Locally Inhibiting CD8+ T Cell Responses
J. Immunol., December 1, 2006; 177(11): 7567 - 7578.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Y. Taraban, T. F. Rowley, D. F. Tough, and A. Al-Shamkhani
Requirement for CD70 in CD4+ Th Cell-Dependent and Innate Receptor-Mediated CD8+ T Cell Priming.
J. Immunol., September 1, 2006; 177(5): 2969 - 2975.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Wuensch, R. H. Pierce, and I. N. Crispe
Local Intrahepatic CD8+ T Cell Activation by a Non-Self- Antigen Results in Full Functional Differentiation
J. Immunol., August 1, 2006; 177(3): 1689 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Cose, C. Brammer, D. J. Zammit, D. Blair, and L. Lefrancois
CD4 T cells inhibit the CD8 T cell response during low-dose virus infection
Int. Immunol., August 1, 2006; 18(8): 1285 - 1293.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
D. G. Fraser, S. R. Leib, B. S. Zhang, R. H. Mealey, W. C. Brown, and T. C. McGuire
Lymphocyte Proliferation Responses Induced to Broadly Reactive Th Peptides Did Not Protect against Equine Infectious Anemia Virus Challenge
Clin. Vaccine Immunol., August 1, 2005; 12(8): 983 - 993.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Xiang, H. Huang, and Y. Liu
A New Dynamic Model of CD8+ T Effector Cell Responses via CD4+ T Helper-Antigen-Presenting Cells
J. Immunol., June 15, 2005; 174(12): 7497 - 7505.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Pinchuk, B. C. Starcher, B. Livingston, A. Tvninnereim, S. Wu, E. Appella, J. Sidney, A. Sette, and B. Wizel
A CD8+ T Cell Heptaepitope Minigene Vaccine Induces Protective Immunity against Chlamydia pneumoniae
J. Immunol., May 1, 2005; 174(9): 5729 - 5739.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. A. Antony, C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C.-C. Chan, C. A. Klebanoff, W. W. Overwijk, et al.
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
J. Immunol., March 1, 2005; 174(5): 2591 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. P. Singh, S. Singh, P. Ravichandran, D. D. Taub, and J. W. Lillard Jr.
Viral Macrophage-Inflammatory Protein-II: A Viral Chemokine That Differentially Affects Adaptive Mucosal Immunity Compared with Its Mammalian Counterparts
J. Immunol., November 1, 2004; 173(9): 5509 - 5516.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Y. Chiang and I. Stroynowski
A Nonclassical MHC Class I Molecule Restricts CTL-Mediated Rejection of a Syngeneic Melanoma Tumor
J. Immunol., October 1, 2004; 173(7): 4394 - 4401.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Lyman, S. Aung, J. A. Biggs, and L. A. Sherman
A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL
J. Immunol., June 1, 2004; 172(11): 6558 - 6567.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Kan-Mitchell, B. Bisikirska, F. Wong-Staal, K. L. Schaubert, M. Bajcz, and M. Bereta
The HIV-1 HLA-A2-SLYNTVATL Is a Help-Independent CTL Epitope
J. Immunol., May 1, 2004; 172(9): 5249 - 5261.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. L. Hanson, S. S. Kang, L. A. Norian, K. Matsui, L. A. O'Mara, and P. M. Allen
CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors
J. Immunol., April 1, 2004; 172(7): 4215 - 4224.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. J. Zaunders, W. B. Dyer, B. Wang, M. L. Munier, M. Miranda-Saksena, R. Newton, J. Moore, C. R. Mackay, D. A. Cooper, N. K. Saksena, et al.
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection
Blood, March 15, 2004; 103(6): 2238 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. C. Derrick, C. Repique, P. Snoy, A. L. Yang, and S. Morris
Immunization with a DNA Vaccine Cocktail Protects Mice Lacking CD4 Cells against an Aerogenic Infection with Mycobacterium tuberculosis
Infect. Immun., March 1, 2004; 72(3): 1685 - 1692.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J.-C. E. Wang and A. M. Livingstone
Cutting Edge: CD4+ T Cell Help Can Be Essential for Primary CD8+ T Cell Responses In Vivo
J. Immunol., December 15, 2003; 171(12): 6339 - 6343.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Beloeil, M. Tomkowiak, G. Angelov, T. Walzer, P. Dubois, and J. Marvel
In Vivo Impact of CpG1826 Oligodeoxynucleotide on CD8 T Cell Primary Responses and Survival
J. Immunol., September 15, 2003; 171(6): 2995 - 3002.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Storni, C. Ruedl, W. A. Renner, and M. F. Bachmann
Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction
J. Immunol., July 15, 2003; 171(2): 795 - 801.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Zhai, L. Meng, R. W. Busuttil, M. H. Sayegh, and J. W. Kupiec-Weglinski
Activation of Alloreactive CD8+ T Cells Operates Via CD4-Dependent and CD4-Independent Mechanisms and Is CD154 Blockade Sensitive
J. Immunol., March 15, 2003; 170(6): 3024 - 3028.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Shedlock, J. K. Whitmire, J. Tan, A. S. MacDonald, R. Ahmed, and H. Shen
Role of CD4 T Cell Help and Costimulation in CD8 T Cell Responses During Listeria monocytogenes Infection
J. Immunol., February 15, 2003; 170(4): 2053 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. W. Lillard Jr, U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity
Blood, February 1, 2003; 101(3): 807 - 814.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. de Jersey, D. Carmignac, T. Barthlott, I. Robinson, and B. Stockinger
Activation of CD8 T Cells by Antigen Expressed in the Pituitary Gland
J. Immunol., December 15, 2002; 169(12): 6753 - 6759.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. S. K. Walker, L. J. Ausubel, A. Chodos, N. Bekarian, and A. K. Abbas
CTLA-4 Differentially Regulates T Cell Responses to Endogenous Tissue Protein Versus Exogenous Immunogen
J. Immunol., December 1, 2002; 169(11): 6202 - 6209.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. G. Gao, V. Khammanivong, W. J. Liu, G. R. Leggatt, I. H. Frazer, and G. J. P. Fernando
Antigen-specific CD4+ T-Cell Help Is Required to Activate a Memory CD8+ T Cell to a Fully Functional Tumor Killer Cell
Cancer Res., November 15, 2002; 62(22): 6438 - 6441.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. C. McKenna, Y. Xu, and J. A. Kapp
Injection of Soluble Antigen into the Anterior Chamber of the Eye Induces Expansion and Functional Unresponsiveness of Antigen-Specific CD8+ T Cells
J. Immunol., November 15, 2002; 169(10): 5630 - 5637.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Zhai, L. Meng, F. Gao, R. W. Busuttil, and J. W. Kupiec-Weglinski
Allograft Rejection by Primed/Memory CD8+ T Cells Is CD154 Blockade Resistant: Therapeutic Implications for Sensitized Transplant Recipients
J. Immunol., October 15, 2002; 169(8): 4667 - 4673.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C. Bourgeois, B. Rocha, and C. Tanchot
A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory
Science, September 20, 2002; 297(5589): 2060 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. M.M. den Haan and M. J. Bevan
Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8- Dendritic Cells In Vivo
J. Exp. Med., September 16, 2002; 196(6): 817 - 827.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. D. Mintern, G. Belz, S. Gerondakis, F. R. Carbone, and W. R. Heath
The Cross-Priming APC Requires a Rel-Dependent Signal to Induce CTL
J. Immunol., April 1, 2002; 168(7): 3283 - 3287.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mintern, J. D.
Right arrow Articles by Heath, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mintern, J. D.
Right arrow Articles by Heath, W. R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stem Cells

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS